Clinical Trial Update: Assessing the Impact of Varenicline on Brain-Behavior Vulnerability [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating varenicline for reducing brain-behavior vulnerability to cocaine cues has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cocaine Use Disorder

Drugs mentioned

• Varenicline (varenicline)

Snippet

Sponsor: University of Pennsylvania | Conditions: Varenicline and the Blunting of Cocaine Cues | Phase 2 | Status: WITHDRAWN